Data on Gene Therapy for LPLD Presented at ASGCT Annual Meeting AMSTERDAM, May 20, 2011 - Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today results from a long-term efficacy study of Glybera (alipogene tiparvovec) that showed improved chylomicron metabolism could be used as a biomarker for increased lipoprotein lipase (LPL) activity in those patients missing the gene that produces this protein. Glybera is a gene therapy product under development for the treatment of lipoprotein lipase deficiency (LPLD) that is currently under review for marketing approval with the European Medicines Agency (EMA).

In Collaboration With the Thai-Journal Citation Index Centre (TCI) and Thailand Research Fund (TRF)

NYBRO, Sweden, May 20, 2011 - The once degraded forests in the Curacautin Valley in Chile have now recovered sufficiently, after hard work over the last decades, to be able to help provide a sustainable living to the people in the area, based on fair trade and responsible forest management principles. Wooden floor maker Kährs from Sweden is the first company in the world to support and purchase dual-labelled material from Chile that meets both FSC and Fairtrade certification standards.